Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

There are currently no available treatment options for more than 90% of the approximately 7,000 rare diseases identified to ...

Sarepta will stop shipping its Duchenne muscular dystrophy gene therapy Elevidys following ongoing discussions with the FDA over safety labeling. The drugmaker said the pause, effective July 22, will ...

Analysts say second fatality heightens safety concerns, raises doubts about future demand Both patients suffered from acute liver failure Sarepta suspends forecast, stops shipments of therapy to some ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...